EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: Safety, efficacy, visual morbidity, and outcomes

Katherine Green iD, Paraskevi Panagopoulou, Felice D'Arco, Patricia O'Hare, Richard Bowman, Bronwen Walters, Christine Dahl, Mette Jorgensen, Pritesh Patel, Olga Slater, Rehana Ahmed, Simon Bailey und 18 weitere

Neuro-Oncology · 2023

DOI: 10.1093/neuonc/noac223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Katherine Green und 29 weiteren Autor:innen. Beteiligte Einrichtung: Great Ormond Street Hospital London, UK. Hauptthemen laut MEDLINE: Optic Nerve Glioma. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bevacizumab is increasingly used in children with pediatric low-grade glioma (PLGG) despite limited evidence. A nationwide UK service evaluation was conducted to provide larger cohort “real life” safety and efficacy data including functional visual outcomes.

Methods

Children receiving bevacizumab-based treatments (BBT) for PLGG (2009–2020) from 11 centers were included. Standardized neuro-radiological (RANO-LGG) and visual (logMAR visual acuity) criteria were used to assess clinical–radiological correlation, survival outcomes and multivariate prognostic analysis.

Results

Eighty-eight children with PLGG received BBT either as 3rd line with irinotecan (85%) or alongside 1st/2nd line chemotherapies (15%). Toxicity was limited and minimal. Partial response (PR, 40%), stable disease (SD, 49%), and progressive disease (PD, 11%) were seen during BBT. However, 65% progressed at 8 months (median) from BBT cessation, leading to a radiology-based 3 yr-progression-free survival (PFS) of 29%. Diencephalic syndrome (P = .03) was associated with adverse PFS. Pre-existing visual morbidity included unilateral (25%) or bilateral (11%) blindness. Improvement (29%) or stabilization (49%) of visual acuity was achieved, more often in patients’ best eyes. Vision deteriorated during BBT in 14 (22%), with 3-year visual-PFS of 53%; more often in patients’ worst eyes. A superior visual outcome (P = .023) was seen in neurofibromatosis type 1-associated optic pathway glioma (OPG). Concordance between visual and radiological responses was 36%; optimized to 48% using only best eye responses.

Conclusions

BBTs provide effective short-term PLGG control and delay further progression, with a better sustained visual (best > worst eye) than radiological response. Further research could optimize the role of BBT toward a potentially sight-saving strategy in OPG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Optic Nerve GliomaChildHumansBevacizumabIrinotecanVisual AcuityUnited Kingdom

Stichwörter der Autor:innen

Bevacizumablow-grade gliomaoptic pathway gliomapediatricvisual outcomes

Substanzen

BevacizumabIrinotecan

Autor:innen und Institutionen

  • Great Ormond Street Hospital London, UK.
  • Nottingham Children's Hospital, UK.
  • Great North Children's Hospital Newcastle, UK.
  • The Royal Marsden Hospital London, UK.
  • John Radcliffe Hospital Oxford, UK.
  • Birmingham Children's Hospital, UK.

ORCID-Profile: Katherine Green

Zitieren

APA

Green, K., Panagopoulou, P., D'Arco, F., O'Hare, P., Bowman, R., Walters, B., Dahl, C., Jorgensen, M., Patel, P., Slater, O., Ahmed, R., Bailey, S., Carceller, F., Collins, R., Corley, E., English, M., Howells, L., Kamal, A., Kilday, J. J., …, & Opocher, E. (2023). A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: Safety, efficacy, visual morbidity, and outcomes. Neuro-Oncology. https://doi.org/10.1093/neuonc/noac223

Vancouver

Green K, Panagopoulou P, D'Arco F, O'Hare P, Bowman R, Walters B, et al. A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: Safety, efficacy, visual morbidity, and outcomes. Neuro-Oncology. 2023. doi:10.1093/neuonc/noac223

BibTeX
@article{Green2023,
  author = {Green, Katherine and Panagopoulou, Paraskevi and D'Arco, Felice and O'Hare, Patricia and Bowman, Richard and Walters, Bronwen and Dahl, Christine and Jorgensen, Mette and Patel, Pritesh and Slater, Olga and Ahmed, Rehana and Bailey, Simon and Carceller, Fernando and Collins, Rhiannon and Corley, Elizabeth and English, Martin and Howells, Lisa and Kamal, Ahmed and Kilday, John-Paul Jp and Lowis, Stephen and Lumb, Blanche and Pace, Erika and Picton, Susan and Pizer, Barry and Shafiq, Ayad and Uzunova, Lena and Wayman, Harriet and Wilson, Shaun and Hargrave, Darren and Opocher, Enrico},
  title = {A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: Safety, efficacy, visual morbidity, and outcomes},
  journal = {Neuro-Oncology},
  year = {2023},
  doi = {10.1093/neuonc/noac223}
}
Kostenlos starten →